Related Experiment Video
Updated: Jul 22, 2025
Assessment of Vascular Function in Patients With Chronic Kidney Disease
Published on: June 16, 2014
Dyslipidemia in Patients with Chronic Kidney Disease: An Updated Overview
1Department of Internal Medicine, Chonnam National University Medical School, Gwangju, Korea.
Insights
Dyslipidemia in chronic kidney disease (CKD) presents unique challenges. This review explores CKD-specific lipid profiles, cardiovascular risks, and the role of lipid-lowering therapy in managing cardiovascular events and slowing CKD progression.
Area of Science:
- Nephrology
- Cardiology
- Clinical Pharmacology
Background:
- Dyslipidemia is a key cardiovascular risk factor.
- CKD patients exhibit distinct lipid profiles compared to the general population.
- Current guidelines offer conservative lipid management for CKD patients due to limited evidence.
Purpose of the Study:
- To review the distinct features of dyslipidemia in CKD.
- To assess the impact of dyslipidemia on cardiovascular outcomes in CKD.
- To evaluate lipid-lowering therapies for cardiovascular risk reduction and CKD progression in CKD patients.
Main Methods:
- Literature review of studies on dyslipidemia in CKD.
- Analysis of evidence for lipid-lowering therapies in CKD.
- Discussion of the relationship between dyslipidemia and CKD progression.
Main Results:
- CKD-associated dyslipidemia differs significantly from general population profiles.
- Evidence on lipid-lowering therapy efficacy in CKD is still evolving.
- Lipid management may influence both cardiovascular events and CKD progression.
Conclusions:
- Understanding CKD-specific dyslipidemia is crucial for effective cardiovascular risk management.
- Further research is needed to optimize lipid-lowering strategies in CKD.
- Targeting dyslipidemia may offer a dual benefit in reducing cardiovascular events and delaying CKD progression.
Abstract:
Dyslipidemia is a potentially modifiable cardiovascular risk factor. Whereas the recommendations for the treatment target of dyslipidemia in the general population are being more and more rigorous, the 2013 Kidney Disease: Improving Global Outcomes clinical practice guideline for lipid management in chronic kidney disease (CKD) presented a relatively conservative approach with respect to the indication of lipid lowering therapy and therapeutic monitoring among the patients with CKD. This may be largely attributed to the lack of high-quality evidence derived from CKD population, among whom the overall feature of dyslipidemia is considerably distinctive to that of general population. In this review article, we cover the characteristic features of dyslipidemia and impact of dyslipidemia on cardiovascular outcomes in patients with CKD. We also review the current evidence on lipid lowering therapy to modify the risk of cardiovascular events in this population. We finally discuss the association between dyslipidemia and CKD progression and the potential strategy to delay the progression of CKD in relation to lipid lowering therapy.
Related Concept Videos
01:24Chronic Kidney Disease II: Clinical Manifestations
01:25Chronic Kidney Disease I: Introduction
01:28Chronic Kidney Disease III: Interprofessional Care
01:18Chronic Kidney Disease IV: Nursing Management
01:22Acute Kidney Injury VI: Nursing Management
01:17Factors Affecting Renal Clearance: Renal Impairment
One condition associated with renal failure is uremia. Uremia is characterized by impaired glomerular filtration and fluid accumulation in the body. This condition hinders the renal clearance of drugs, resulting in drug accumulation and potential...